^
Association details:
| Biomarker: | CHEK2 mutation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Rubraca (rucaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations
Excerpt:
...- Germline mutation in one or more homologous recombination DNA-repair genes (BRCA1, BRCA2, ATM, CHEK2, NBN, RAD50, RAD51C, RAD51D, PALB2, MRE11, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM) as documented by a clinical CLIA-grade, genetic test (including but...
Trial ID:
Source:
Title:
TRIUMPH: Phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations.
Published date:
02/13/2023
Excerpt:
12 pts were enrolled, 7 with BRCA1/2 and 5 with CHEK2 muts. The confirmed PSA50 response rate to rucaparib was 41.7% (N=5/12, 95% CI: 19.3-68.1%)...In pts with measurable disease, the ORR was 60% (N=3/5, all with BRCA2). Median rPFS on rucaparib was 10.3 months (95% CI: 4.0 mo - NR)....Rucaparib can induce clinical responses in a biomarker-selected PCa population without concurrent ADT.
DOI:
10.1200/JCO.2023.41.6_suppl.190
Trial ID:
